Reducing Topical Drug Waste in Ophthalmic Surgery

*Multisociety Position Paper*

Unnecessary waste of perioperative topical ophthalmic medications (eyedrops and eye ointments) significantly increases the cost and carbon footprint of ophthalmic surgery as well as the risk of periodic drug shortages. This document, endorsed by the American Society of Cataract and Refractive Surgery (ASCRS), the American Academy of Ophthalmology (AAO), the American Glaucoma Society (AGS), and the Outpatient Ophthalmic Surgery Society (OOSS), establishes recommendations to reduce costly and unnecessary waste of topical medication.

**Background**

Beyond the rising economic burden of our healthcare system, there is increasing awareness of its disproportionately large carbon footprint and environmental impact. The healthcare sector generates approximately 9% of total greenhouse gas emissions in the United States and is the second largest source of landfill trash. Operating rooms (OR) contribute up to 30% of a hospital’s waste. Cataract surgery is one of the most common surgical procedures in medicine, with a large projected increase in global volume. This gives ophthalmology a unique opportunity and imperative to prioritize the financial and environmental sustainability of quality eyecare delivery.

A British study reported that one phacoemulsification (contemporary cataract surgery) in the United Kingdom generated the same carbon emissions (~130 kg CO₂eq) as driving a car 500 km (310 miles). The procurement sector was the major source of CO₂eq emissions with supply chains for medical equipment and pharmaceuticals accounting for 33% and 18% of this sector, respectively. By comparison, phacoemulsification at the Aravind hospital system in India was found to generate the same carbon emissions (~6 kg CO₂eq) as driving a car 23 km (14 miles). The largest difference was attributed to reuse of most surgical supplies and pharmaceuticals at Aravind. Despite this, their endophthalmitis rate for phacoemulsification was only 0.01% in more than 335,000 consecutive cases, which is lower than the rate (0.04%) reported by the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight).

Prescription drugs account for approximately 10% of healthcare costs in the U.S. A 2019 study analyzed the economic and environmental impact of topical, injectable, and systemic medication waste at four centers performing cataract surgery. Nearly half of all drugs (and two-thirds of topical drugs) were discarded after a single use across all four sites for up to an estimated $195,000 wasted annually per site on unused medication. Discarded topical eyedrops and ointments from unused or partially used containers accounted for an approximate cost of $150 per case. The authors estimated that this drug waste generated 23,000 to 105,000 metric tons of unnecessary CO₂eq emissions annually in the U.S. Aside from cost and environmental considerations, needless waste also increases the potential for and impact of periodic drug shortages.
The Ophthalmic Instrument Cleaning and Sterilization (OICS) Task Force comprised of specialists representing ASCRS, AAO, AGS, and O OSS, has previously published ophthalmology-specific guidelines for surgical instrument processing and sterilization. One focus of this multisociety task force is the reduction of unnecessary waste in ophthalmic surgery. An OICS Task Force survey in 2020 of more than 1,300 cataract surgeons and nurses found that 93% said they believed operating room (OR) waste is excessive and should be reduced, 91% were concerned about climate change, and 78% felt that we should seek ways to safely reuse supplies and instruments. There was strong consensus that regulatory policies and manufacturer’s printed instructions for use, which prohibit reuse of many potentially multiuse products and medications, are major contributors to excessive waste.

This statement provides three recommendations regarding the safe and responsible use of perioperative topical medications. These consensus recommendations are based on a review of published studies and discussions with multiple regulatory and accrediting organizations in the U.S. and have been endorsed by the four eyecare specialty societies that this task force represents.

** Recommendation #1: Topical drugs in multidose containers can be used on multiple patients in surgical facilities if proper guidelines are followed.**

In 1964, the U.S. Food and Drug Administration (FDA) finalized regulations allowing topical drugs to be packaged in multidose containers containing antimicrobial preservatives and labelled with an expiration date. Two large studies performed at the University of Utah established that proper reuse of eye medication bottles on multiple patients did not contribute to increased rates of endophthalmitis. In 2015, ASCRS released a position statement supporting “the established practice of utilizing multidose eye drops on multiple patients, when proper protocols are followed”. A 2021 study evaluated bottle-tip contamination when multiuse ophthalmic solutions were instilled in over 1,800 patients prior to eye surgery. When proper guidelines were followed, there was no bottle-tip or solution contamination detected by videographic and microbiological analysis.

Ninety-eight percent of ophthalmologist respondents to the OICS Task Force OR waste survey said they were willing to consider or were already using eyedrops from multidose bottles on multiple perioperative patients. Nearly half of all respondents were already using topical mydriatics (48%), antibiotics (45%), nonsteroidal anti-inflammatory drugs (38%), anesthetics (43%) and intraocular pressure-lowering medications (42%) on multiple patients from the multidose container. These surgeons reusing multidose bottles were more likely to be operating at ambulatory surgery centers (ASCs) than at hospital outpatient departments (p <0.0001). In 2021 O OSS surveyed its member ASCs regarding their use of perioperative topical medication (unpublished): 98% were using multidose bottles of topical medications on multiple perioperative patients. When directly queried, none of the 119 responding facilities reported ever having a case of endophthalmitis attributed to this practice. Taken together, these two surveys suggest that many surgeons who are not reusing multidose bottles are practicing at hospital outpatient departments.

However, some surgical facilities require (or have been directed by regulatory agencies to require) that multiuse bottles of eyedrops be discarded after use on a single patient. For example, the Utah Valley Regional Medical Center (Provo, Utah) and the Surgical Eye Center of Morgantown (Morgantown, West Virginia) were initially directed during their accreditation processes by The Joint Commission (TJC) auditors to not reuse multiuse bottles of topical medication following instillation on a single patient. Following appeals, both organizations received approval from TJC and/or the West Virginia Office of Health Facility and Licensure
Certification to resume reusing multidose topical bottles according to safe handling and administration guidelines established by AAO.\textsuperscript{19,20}

This task force contacted the Ambulatory Association for Ambulatory Health Care (AAAHC) accreditation organization in 2021 regarding this recommendation. AAAHC, through its public relations firm (L.C. Williams and Associates, Chicago), wrote that its “\textit{standards allow multidose eyedrops, provided that the medication is labeled, handled per CDC (Centers for Disease Control) guidelines, and administered and stored according to policies, manufacturer instructions, and best practice recommendations. Staff must understand safe practice and apply infection control techniques.”}

\textbf{Recommendation \#2: Topical drugs in multidose containers can be used until the manufacturer’s labeled date of expiration if proper guidelines are followed.}

In the 2021 O OSS survey regarding ASC policies, multidose topical eyedrop bottles that were not empty were discarded either at the end of the day (9\%), the week (3\%), or the month (72\%) by most responding ASCs (unpublished). Only 12\% continued using the bottle until the medication’s labelled date of expiration. Multidose topical medication bottles contain antimicrobial preservatives that ensure sterility with proper use up until the stated expiration date per the manufacturer’s package insert. This task force contacted the FDA, the TJC, the CDC, and the American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF) for clarification regarding the duration that multidose topical formulations could be used at surgical facilities.

In a 2021 editorial, Wiley Chambers, MD, director of the FDA Office of Specialty Medicine, Division of Ophthalmology, wrote that “\textit{Products not labeled as single-dose or single-use ophthalmic products are not intended to be limited in use to a single patient. When stored as labeled, products can be expected to be used safely after opening until the expiration date included on the bottle. The location of the use of an ophthalmic drug product does not influence the expiration date except where the location may alter the storage temperature of the bottle. Neither TJC nor the USP (United States Pharmacopeia) has requirements to use ophthalmic drug products within 28 days. Each historically has discussed 28-day limitations for systemically injected products, but neither has ever included, nor has meant to include ophthalmic products in those discussions. Direct communication with TJC has confirmed that no 28-day limitation for ophthalmic products by TJC exists.”}\textsuperscript{21}

In a 2021 communication with our task force, TJC’s Robert Campbell, PharmD, BCSCP, clinical director for the Standards Interpretation Group and Director of Medication Management, wrote that “\textit{the 28-day expiration dating used for multidose injectable medications does not apply to topical agents such as ophthalmic drops/ointments. The manufacturer’s package insert provides expiration dates for the particular product.”} AAAASF’s Ilana Wolf, RN, replied by email that “\textit{When using multi-dose eye drops in a surgical facility, it is acceptable for expiration dates to follow the manufacturer’s recommendations if multi-dose eye drops are labeled, handled per CDC guidelines, and administered and stored according to policies, manufacturer instructions, and best practice recommendations. These facilities must monitor and perform surveillance of the administration of multi-dose eye drops as part of their infection control program. Facility staff must be trained and have ongoing competencies documented specific to multi-dose eye drops.”} Subsequent communication with CDC confirmed that its guidelines are similar.\textsuperscript{22}

Confusion over policies established by the Centers for Medicare & Medicaid Services (CMS) may contribute to inconsistent practices and regulatory rulings on this issue. The 2015 CMS Center for Clinical Standards and Quality/Survey and Certification Group State Operations Provider Certification Manual and Surveyor Infection Control Worksheet specifically references a maximum 28-day expiration date for infusible and injectable medications.\textsuperscript{23} The absence of specific regulations for when multidose eyedrop bottles must be discarded
appears to have caused some surveyors to apply the 28-day expiration policy for injectables to topical eye medications. Our direct communication with the CMS Survey and Certification Group has confirmed (see above) that the policy for injectable medications does not apply to multidose eyedrop bottles.

Microbial contamination of the bottle tip could result from contact with the nurse’s fingers or the patient’s ocular surface or adnexa. Facility staff must be trained in the proper eyedrop instillation technique. Multidose bottles whose tips become contaminated should be immediately discarded. Following discussions with our task force, the American Society of Ophthalmic Registered Nurses (ASORN) has published a multidose eyedrop application protocol on its website. This protocol adheres to CDC infection control guidelines and indicates that eyedrops may be used until the manufacturer expiration date or facility end-use date with proper storage and administration technique.

**Recommendation #3: When applicable, patients should be able to bring their partially used medication home for postoperative use.**

Some surgical patients require specific topical medications not used for other patients. If that drug needs to be continued postoperatively, it is wasteful and unnecessarily burdensome to discard the newly opened multiuse bottle and instead require the patient to purchase the same medication through an outpatient pharmacy. This approach may be facility-specific or the result of state-specific pharmacy dispensing regulations. These state rules may require surgical facilities to label topical medication bottles with instructions and provide medication counseling for patients to take a bottle home for continued care.

In the 2020 OICS Task Force OR waste survey, 26% of ophthalmologists currently send topical pharmaceuticals administered in the OR home with patients; 67% would be willing to consider this, and only 4% were unwilling to do this. In a 2019 Illinois Society of Eye Physicians and Surgeons survey, only 40% of responding ophthalmologists indicated that medications ordered at the surgical facility could be taken home by the patient postoperatively. Reasons preventing this practice included facility regulations (49%), state regulations (23%), medications being discarded (38%), and pharmacy constraints. The latter included inability to print labels (28%), insufficient pharmacy staffing (23%), and logistical obstacles to patient counseling by pharmacists (36%). Patient barriers to repurchasing these same drugs from an outpatient pharmacy included transportation and support issues (69%) and financial barriers (90%). Of surgeons, 42% felt that the inability to provide medications directly from the facility would adversely affect quality of care, including increased risk of infection or intraocular inflammation.

Because there is wide regional variation in pharmaceutical dispensing regulations, obstacles to this recommendation may need to be addressed at the state level. What has been accomplished in Illinois may guide and serve as an example to others. The Chicago and Illinois State Medical Societies introduced a resolution to the Illinois General Assembly in 2020, “Topical Operating Room or Emergency Room Medications for Post-Discharge Patient Use.” Illinois SB579 was signed into law in 2021 as PA 102-0155, with support from other surgical subspecialty societies including the Illinois Society of Plastic Surgeons, The Chicago Laryngological and Otological Society, the Illinois Dermatological Society, and the Illinois College of Emergency Room Physicians. This legislation stipulates that topical medications ordered at least 24 hours preoperatively and used in the OR must be properly labeled before the unused portion can be given to patients for post-discharge care. Physicians provide the medication counseling following surgery. In 2021, the American Medical Association House of Delegates unanimously adopted a modification of the Illinois resolution titled “Permitting the Dispensing of Stock Medications for Post-Discharge use and the Safe Use of Multidose Eyedrops on Multiple patients,” which had been endorsed by multiple specialty societies, including AAO, ASCRS, AGS, and ASORN.
We recommend reducing regulatory obstacles to the safe and well-accepted practice of allowing patients to take a multidose bottle of topical medication home for continued use after it was opened and administered to them at the surgical facility. AAO has established a Topical Medical Waste Reduction Act link to a legislative template based on the Illinois law to assist ophthalmologists and other interested individuals to develop legislative efforts in their states.30

Conclusion

These three recommendations address ways to reduce topical drug waste, while keeping patient safety paramount. There is consensus within ophthalmology that excessive surgical drug waste unnecessarily increases the cost and carbon footprint of eye surgery, particularly given the high volume of procedures such as cataract surgery. With increases in surgical volume anticipated, waste is neither economically nor environmentally sustainable and could make periodic drug shortages more likely and the impact more severe.

REFERENCES

30. AAO Topical Medical Waste Reduction Act template: https://www.dropbox.com/s/y7bl1pilh9ftfjc/MedicalWastePacket.pdf?dl=0

Prepared by the Ophthalmic Instrument Cleaning and Sterilization (OICS) Task Force (David F. Chang, MD, Cathleen M. McCabe, MD, co-chairs) and its Surgical Pharmaceutical Waste Subcommittee (David J. Palmer, MD, Alan L. Robin, MD, co-chairs)

**OICS Task Force**: Diane Blanck, Richard S. Hoffman, MD, Simon Holland, MD, John Hovanesian, MD, Nikki Hurley, RN, Flora Lum, MD, Francis S. Mah, MD, Nick Mamalis, MD, Robert B. Nelson, PA-C, Michael X. Repka, MD, Neal H. Shorstein, MD, Andrew Sorenson, MD, Cassandra L. Thiel, PhD, Jeffrey Whitman, MD

**OICS Surgical Pharmaceutical Waste Subcommittee**: Surendra Basti, MD, Michelle Churches MSN, RN, Nicholas J Hackett, MD, Barbara Ann Harmer, MHA, BSN, RN, Darby Miller, MD, Emily M. Schehlein, MD, Aakriti Garg Shukla, MD, Ruth D. Williams, MD, Annie M. Wu, MD